正在加载公司
Danaher Corp.
DHR · NYSE · ·
下次财报：2026年10月21日 · 开盘前
US$226.11-0.6%9月29日 收盘
- 1M
- +4.6%
- 6M
- +23.2%
- 1Y
- +14.7%
- 5Y
- -15.9%
Danaher sells instruments, supplies, and services used in biological research, drug manufacturing, and medical testing.
DHR · NYSE · ·
下次财报：2026年10月21日 · 开盘前
US$226.11-0.6%9月29日 收盘
Danaher sells instruments, supplies, and services used in biological research, drug manufacturing, and medical testing.
各项收入占比是对six months ended June 26, 2026的估算，并非来自已提交报告的数字。
Cytiva bioprocessing products
Filters, resins, liquids, single-use equipment, and services that drugmakers use to develop and manufacture biological medicines.
Pall filtration products
Filters and related equipment that remove contaminants from liquids and gases used in medicine, research, food production, electronics manufacturing, and other industries.
Biacore 8S
A Cytiva instrument that lets researchers test how potential drug molecules interact with their targets.
SCIEX mass spectrometers
Instruments that identify and measure molecules in samples, used in drug research, clinical testing, and food and environmental testing.
Beckman Coulter clinical testing systems
Laboratory instruments, tests, and software that analyze blood and other body samples to help diagnose and monitor health conditions.
Cepheid GeneXpert tests
Systems and tests that detect genetic material from organisms or diseases, including tests used in hospitals and other care settings.
三项评分，每一项都是相对我们在Diagnostics and Research覆盖的 43 家公司 的百分位。刻意分开而不揉成一个总分：便宜、上涨和经营得好是三件不同的事，一个数字会把它们是哪一件藏起来。
低于行业内多数公司
最近一个月被刻意剔除：回报往往在 7 到 12 个月内延续，而最新的一个月往往反转。这描述的是股价已经走过的路，不说明它接下来会怎么走。
高于行业内多数公司
这些是收益率，所以数值越高越便宜——亏损的公司会排在最后，而不是被剔除。便宜不等于好：高收益率往往意味着股价是有原因才跌下来的。 五项指标齐全。
1 项检验未披露
管理层怎么使用这笔钱——只按财报能回答的部分计分，绝不按占总数的比例计分。
这是对该公司在同行中所处位置的描述，不是投资建议。 评分更新于 2026年9月30日。
Danaher owns more than 15 operating companies grouped into biotechnology, life sciences, and diagnostics. Their products help researchers study cells and other biological material, help drugmakers make biological medicines, and help healthcare workers test samples and monitor patients. Many products are used up or replaced regularly, so customers buy supplies as well as instruments and services.
基于 Danaher Corp. 自己向 SEC 提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
生意在变大吗，它是否创造真实的现金？
显示 Danaher Corp. 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年9月。